Post-translational modifications, a key process in CD36 function: Lessons from the spontaneously hypertensive rat heart

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 1, 2011, Pages 99-108

  Lauzier, Benjamin ^a,b   Merlen, Clémence ^a,b   Vaillant, Fanny ^a,b   McDuff, Janie ^a   Bouchard, Bertrand ^a   Beguin, Pauline C ^a   Dolinsky, Vernon W ^c   Foisy, Sylvain ^a   Villeneuve, Louis R ^a   Labarthe, François ^d   Dyck, Jason R B ^a   Allen, Bruce G ^a,b   Charron, Guy ^a   Des Rosiers, Christine ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Cd36; Energy metabolism; Isolated working heart; N glycosylation; Post translational modifications

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BETA N ACETYLGLYCOSAMINE; CD36 ANTIGEN; LONG CHAIN FATTY ACID; MALONYL COENZYME A; MEMBRANE PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD36 GENE; CONTROLLED STUDY; EX VIVO STUDY; FATTY ACID OXIDATION; GENE; GLYCOSYLATION; HEART DISEASE; HEART HYPERTROPHY; HEART MUSCLE METABOLISM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIGENS, CD36; FATTY ACIDS; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOPROTEINS; GLYCOSYLATION; HEART; HYPERTENSION; IMMUNOBLOTTING; MALONYL COENZYME A; MUTATION; ORGAN CULTURE TECHNIQUES; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, INBRED SHR; RATS, WISTAR; TRIGLYCERIDES;

RATTUS;

EID: 79956314101     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.04.001     Document Type: Article

References (40)

1. Febbraio M., Silverstein R.L. CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 2007, 39:2012-2030.
2. Glatz J.F., Luiken J.J., Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev 2010, 90:367-417.
3. Rac M.E., Safranow K., Poncyljusz W. Molecular basis of human CD36 gene mutations. Mol Med 2007, 13:288-296.
4. Hoosdally S.J., Andress E.J., Wooding C., Martin C.A., Linton K.J. The human scavenger receptor CD36: glycosylation status and its role in trafficking and function. J Biol Chem 2009, 284:16277-16288.
5. Morii T., Ohno Y., Kato N., Hirose H., Kawabe H., Hirao K., et al. CD36 single nucleotide polymorphism is associated with variation in low-density lipoprotein-cholesterol in young Japanese men. Biomarkers 2009, 14:207-212.
6. Noel S.E., Lai C.Q., Mattei J., Parnell L.D., Ordovas J.M., Tucker K.L. Variants of the CD36 gene and metabolic syndrome in Boston Puerto Rican adults. Atherosclerosis 2010, 211:210-215.
7. Love-Gregory L., Sherva R., Sun L., Wasson J., Schappe T., Doria A., et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet 2008, 17:1695-1704.
8. Hajri T., Ibrahimi A., Coburn C.T., Knapp F.F., Kurtz T., Pravenec M., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 2001, 276:23661-23666.
9. Labarthe F., Khairallah M., Bouchard B., Stanley W.C., Des Rosiers C. Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. Am J Physiol Heart Circ Physiol 2005, 288:H1425-H1436.
10. Tanaka T., Sohmiya K., Kono T., Terasaki F., Horie R., Ohkaru Y., et al. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol Cell Biochem 2007, 299:23-35.
11. Vincent G., Khairallah M., Bouchard B., Des Rosiers C. Metabolic phenotyping of the diseased rat heart using 13C-substrates and ex vivo perfusion in the working mode. Mol Cell Biochem 2003, 242:89-99.
12. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999, 21:76-83.
13. Glazier A.M., Scott J., Aitman T.J. Molecular basis of the Cd36 chromosomal deletion underlying SHR defects in insulin action and fatty acid metabolism. Mamm Genome 2002, 13:108-113.
14. Bonen A., Han X.X., Tandon N.N., Glatz J.F., Lally J., Snook L.A., et al. FAT/CD36 expression is not ablated in spontaneously hypertensive rats. J Lipid Res 2009, 50:740-748.
15. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
16. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
17. Slama M., Ahn J., Varagic J., Susic D., Frohlich E.D. Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: effects of hypertension and age. Am J Physiol Heart Circ Physiol 2004, 286:H181-H185.
18. Doggrell S.A., Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998, 39:89-105.
19. Mann M., Jensen O.N. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003, 21:255-261.
20. Khairallah R.J., Khairallah M., Gelinas R., Bouchard B., Young M.E., Allen B.G., et al. Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation. J Mol Cell Cardiol 2008, 45:230-239.
21. Dyck J.R., Barr A.J., Barr R.L., Kolattukudy P.E., Lopaschuk G.D. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 1998, 275:H2122-H2129.
22. Gelinas R., Labarthe F., Bouchard B., Mc D.J., Charron G., Young M.E., et al. Alterations in carbohydrate metabolism and its regulation in PPARalpha null mouse hearts. Am J Physiol Heart Circ Physiol 2008, 294:H1571-H1580.
23. Khairallah M., Khairallah R., Young M.E., Dyck J.R., Petrof B.J., Des Rosiers C. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol 2007, 43:119-129.
24. Beguin P.C., El-Helou V., Assimakopoulos J., Clement R., Gosselin H., Brugada R., et al. The phenotype and potential origin of nestin+cardiac myocyte-like cells following infarction. J Appl Physiol 2009, 107:1241-1248.
25. Kuang M., Febbraio M., Wagg C., Lopaschuk G.D., Dyck J.R. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 2004, 109:1550-1557.
26. Vinals M., Xu S., Vasile E., Krieger M. Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their effects on HDL binding and selective lipid uptake. J Biol Chem 2003, 278:5325-5332.
27. Luo B., Parker G.J., Cooksey R.C., Soesanto Y., Evans M., Jones D., et al. Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes. J Biol Chem 2007, 282:7172-7180.
28. Ngoh G.A., Facundo H.T., Zafir A., Jones S.P. O-GlcNAc signaling in the cardiovascular system. Circ Res 2010, 107:171-185.
29. Okayama H., Hamada M., Kawakami H., Ikeda S., Hashida H., Shigematsu Y., et al. Increased contraction of myocytes isolated from the young spontaneously hypertensive rat: relationship between systolic and diastolic function. Am J Hypertens 1998, 11:349-356.
30. Dolinsky V.W., Chan A.Y., Robillard Frayne I, Light P.E., Des Rosiers C, Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
31. Keizer H.A., Schaart G., Tandon N.N., Glatz J.F., Luiken J.J. Subcellular immunolocalisation of fatty acid translocase (FAT)/CD36 in human type-1 and type-2 skeletal muscle fibres. Histochem Cell Biol 2004, 121:101-107.
32. Vistisen B., Roepstorff K., Roepstorff C., Bonen A., Kiens B., van Deurs B Sarcolemmal FAT/CD36 in human skeletal muscle colocalizes with caveolin-3 and is more abundant in type 1 than in type 2 fibers. J Lipid Res 2004, 45:603-609.
33. Eyre N.S., Cleland L.G., Tandon N.N., Mayrhofer G. Importance of the carboxyl terminus of FAT/CD36 for plasma membrane localization and function in long-chain fatty acid uptake. J Lipid Res 2007, 48:528-542.
34. Stuart L.M., Deng J., Silver J.M., Takahashi K., Tseng A.A., Hennessy E.J., et al. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol 2005, 170:477-485.
35. Luiken J.J., Coort S.L., Willems J., Coumans W.A., Bonen A., van der Vusse G.J., et al. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003, 52:1627-1634.
36. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 1993, 3:97-130.
37. Kukuruzinska M.A., Lennon K. Protein N-glycosylation: molecular genetics and functional significance. Crit Rev Oral Biol Med 1998, 9:415-448.
38. Jaeken J., Carchon H. The carbohydrate-deficient glycoprotein syndromes: an overview. J Inherit Metab Dis 1993, 16:813-820.
39. Laczy B., Hill B.G., Wang K., Paterson A.J., White C.R., Xing D., et al. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol 2009, 296:H13-H28.
40. Laczy B., Fülöp N., Onay-Besikci A, Des Rosiers C., Chatham JC. Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein PLOS One 2011, 6:e18417.